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and steroid treatment, ESR &/or CRP; current non-RA drugs, and co-morbidities.
R2 values ranged from 0.277 (no inflammatory marker) to 0.331 (with CRP), while
mean HAQ prediction error was 0.13 (0.27). Step 2&hibar;Costs were assessed in
8,423 GPRD cases with similar gender balance (69.8% female) but older mean 64
years). Predicted HAQ (pHAQ) scores ranged from 0.45 to 3.00, with a mean of
1.78 (0.31). Mean annual cost of care in this population was £2792 (£5633), with
46% from hospital admissions, 24% prescriptions, 20% GP consultations, 11%
outpatient attendances, and 11% investigations. Step 3&hibar;Total
costs (pCOST) were optimally predicted from EXP^(5.613(Age*0.005)
(pHAQ*1.185) (Age*pHAQ*-0.001)). pCOST has an exponential correlation to
pHAQ (R20.986; EXP^(342(pHAQ*1.188)). CONCLUSIONS: Age-adjusted pre-
dicted total health care costs for RA patients increased exponentially across the
range of estimated disability. Although higher than published estimates, exclusion
of support-service costs suggests these values may be conservative.
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OBJECTIVES: To estimate the treatment costs of rheumatoid arthritis, psoriasis,
Crohn’s disease and ulcerative colitis in the Brazilian private health care system.
METHODS: Treatment costs were gathered from a claims database with over four
million beneficiaries for rheumatoid arthritis (AR), psoriasis (Pso), Crohn’s disease
(CD) and ulcerative colitis (UC). Patients were identified according to CID10 codes
and observed between June 2009 and August 2011. Treatment costs included hos-
pitalization, drug, procedures, exams, equipment and other costs. RESULTS: In
total 269 patients received treatment for AR, Pso, CD and UC in the Brazilian health
care system, with an expenditure of about R$ 13 million. Over 78% of expenditure
was due to drug spending, followed by hospitalization (8%), and materials (6%).
Over R$ 8.2 million (63%) were spent with 116 CD and UC patients, resulting in an
average cost of R$70.939,84 per patient. For 144 AR patients, expenditure totaled R$
4.4 million (34% of the total spending) with an average cost per patient of
R$30.834,06. Nine patients were identified with psoriasis, with a total spending of
R$334.756 (2,57%), an average of R$ 37.195,11 per patient. On average, AR patients
were hospitalized for 17 days with a total cost of R$181.422, followed by CD and UC
patients hospitalized for 15 days on averagewith a total cost of R$ 965.507. Psoriasis
patients were hospitalized on average for 4 days, with R$ 15.953 spend on average.
CONCLUSIONS: Drug spending is the main driver behind health care spending in
AR, Pso, Cd and UC in the Brazilian private health care system. Despite the lowest
hospital stay, on average psoriasis patients spend more than RA patients in the
hospital. Psoriasis represents the lowest share of total costs due to a low number of
patients observed with this disease, indicating these patients might not have ac-
cess to treatment.
PMS21
MAPPING HEALTH CARE COSTS TO CLINICAL DISEASE ACTIVITY WHERE COST
DATA IS LACKING – A NOVEL APPROACH USING MEDICAL EXPENDITURE
PANEL SURVEY DATA WITH THE CORRONA RHEUMATOID ARTHRITIS DISEASE
REGISTRY
Ingham M1, Ghushchyan VH2, Reed G3, Decktor D4, Bolce R4, Bolge S1, Nair KV2
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2University of Colorado, Denver, Aurora, CO,
USA, 3University of Massachusetts Medical School, Worcester, MA, USA, 4Janssen Services, LLC,
Horsham, PA, USA
OBJECTIVES: To estimate incremental health care expenditures related to changes
in disease activity scores for the Clinical Disease Activity Index (CDAI) and the
modified Health Assessment Questionnaire (mHAQ) in rheumatoid arthritis (RA)
patients.METHODS: This analysis was based on a cross-sectional sample of 19,011
RA patients from the CORRONA Registry using last visit after January 1, 2009. A
mapping algorithm regressed CDAI and mHAQ severity scores from CORRONA
onto a clinically relevant group from theMedical Expenditure Panel Survey (MEPS),
based on socio-demographics, co-morbidities, and patient specific characteristics
that are available in both datasets. This analysis used ordinary least squares re-
gression andTobitmodels. Statistically significant coefficients obtained from these
regressions were used to generate CDAI and HAQ scores for all RA patients within
MEPS. Subsequently, a generalized linear model (GLM) with logarithmic transfor-
mation of annual expenditures determined the incremental costs associated with
worsening in CDAI and mHAQ scores. Total healthcare expenditures (THCE) by
pre-determined levels of RA severity were estimated. Incremental cost-per-unit of
worsening in outcome was inferred from these models. RESULTS: Relative to low
disease activity levels, patients at moderate and high disease activity levels expe-
rienced incremental increases in THCE of $3051 (95% CI: $1274, $4828) and $6221
(95% CI: $2110, $10332) respectively. A point worsening in CDAI is associatedwith a
$601 (95% CI: $359, $843) increase in annual THCE. For each 0.1 point worsening in
mHAQ there was a $621 (95% CI: $317, $925) increase in THCE. Data for the sub-
group of patients over 65 years of age demonstrated the same trend but had greater
absolute incremental costs. CONCLUSIONS: It is feasible to map clinical severity
data onto economic panel data to predict marginal economic effects of increasing
severity in RA. Patients able to attain, and maintain, lower disease activity levels
may save the health care system substantial costs.
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OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and
higher healthcare cost. This study aimed to assess the direct medical costs of
rheumatoid arthritis (RA) and to characterize predictors of these costs.METHODS:
A total of 349 RA patients were randomly selected by stratified two-stage sampling
from the China Basic Health Insurance database in 2009. All information of patient
demographic characters, clinical and costswere collected for the analysis.We used
generalized estimating equations to examine potential predictors of the costs.
RESULTS: Among 349 RA patients (mean age  58.9 years; 67% female), The mean
length-of-staywas 19.0 days for RApatientswith basicmedical insurance for urban
employees and 15.5 days for those with basic medical insurance for urban resi-
dents. The average inpatient cost was RMB8521.5 yuan (median: 6608.7, IQR:
4223.5-10383.3) and the average drug cost accounts for 49.95% of the total cost
(mean: 4256.9; median: 3681.7, IQR: 1973.7-5295.3). The multiple linear regressions
showed that the hospital cost of Patients with basic medical insurance for urban
employees had 39.6% higher costs than those with basic medical insurance for
urban residents(p0.001). Patients from tertiary hospitals had 97.8% higher costs
than those from primary hospitals; (P  0.001) and patients from municipalities
had 46.0% higher costs than those from prefecture-level cities. (P  0.01).
CONCLUSIONS: Patients with RA is associated with high hospital costs. Costs are
now driven predominantly by the cost of drugs, primarily biologic agents. and
sociodemographic characteristics such as types of health insurance and levels of
hospitals also play an important role in determination of costs.
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OBJECTIVES: To estimate the annual cost of etanercept, adalimumab and inflix-
imab per treated RA patient using US managed care drug utilization data.
METHODS: Adult patients who used tumor necrosis factor inhibitors (TNF-inhibi-
tors), specifically etanercept, adalimumab, or infliximab, were identified in the
MarketScan Commercial database between January 1, 2005 and June 30, 2009 and
were followed for 1 year (study enddatewas June 30, 2010). The index eventwas the
first use of TNF-inhibitors following a diagnosis for RA. Patients were classified as
either initiating or continuing TNF-inhibitor treatment based on their utilization
during the 6 months prior to index (pre-index period). Patients with other condi-
tions treated with TNF-inhibitors were excluded. Mean monthly dose was com-
puted for patients on therapy; September 2011 wholesale acquisition costs were
applied to mean monthly dose and 2011 Medicare Physician Fee Schedule was
applied to related drug administrations. Costs from restarting index TNF-inhibitor
therapy after discontinuation and costs from switching to a different TNF-inhibitor
were attributed to patients’ index TNF-inhibitor therapy. RESULTS: In total, 13,850
patients met the study criteria (7,035 etanercept; 3,892 adalimumab; 2,923 inflix-
imab); 44% of patients were initiators. Patient characteristics were similar across
treatment groups (mean age50.5, SD10; 76% female). The mean annual TNF-
inhibitor cost per treated RA patient was $14,892 for etanercept, $18,381 for adali-
mumab, and $23,265 for infliximab. For initiators, mean annual TNF-inhibitor cost
per treated RA patient was $14,149 for etanercept, $17,124 for adalimumab, and
$19,999 for infliximab; among patients continuing therapy, mean annual costs
were $15,423 for etanercept, $19,845 for adalimumab, and $25,232 for infliximab.
CONCLUSIONS: Etanercept had the lowest mean annual TNF-inhibitor cost per
treated RA patient when using actual drug utilization from a US managed care
population. The mean annual TNF-inhibitor costs per treated RA patient on adali-
mumab and infliximab were approximately 23% and 56% higher than etanercept,
respectively.
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OBJECTIVES: Road Traffic Injuries are considered as one of the leading causes of
mortality andmorbidity all over theworld and it is estimated that every day around
3000 people are killed in traffic injuries. Injuries caused by motorcycle accidents
constitute a major preventable burden in developing countries and contribute sig-
nificantly to the overall traffic injuries. The consequences include acute medical,
long-term medical, short-term work loss, long-term disability and lost quality of
life. This study aims to determine the direct cost for treatment incurred due to
Motorcycle incidents at a public tertiary care hospital.METHODS: Thiswas a cross-
sectional observational study. The data was reviewed from March to June 2009
during August 2009. All motorbike accident victims presented to emergency de-
partment were included in the study. Demographic, Injury related and cost data
was collected from victims or their attendants by using structured pre-tested ques-
tionnaire by experienced data collectors over phone. Chi-square test was used to
find out statistical significance at 95% confidence level. RESULTS: In total 151 pa-
tients were presented at emergency department during the period from motorcy-
cle accidents and the datawas received from 107 patients. Of these, 83%were adult
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